Bayer at a Crossroads: $7.25 Billion Settlement and Supreme Court Ruling Loom

Bayer’s stock finds itself caught between two powerful legal magnets this June. While Jefferies analysts have sharply raised their price target, the shares continue to slide as investors weigh a potentially transformative settlement deadline and a Supreme Court ruling that could wipe out the majority of glyphosate lawsuits. The ADRs closed Friday at $10.56 in New York, shedding nearly 5% over the week, while the Xetra-listed shares fell 5.1% to €36.53 — below both the 50-day moving average of €37.91 and the 200-day average of €38.91.

Jefferies unveiled a significant upgrade on May 29, with new pharma analyst Michael Leuchten boosting the target from €25 to €40 — a 60% jump — based on a sum-of-the-parts analysis that pegs the fair value at €45. Yet the rating remains at "Hold" and the downside scenario is stark: if legal risks escalate, the stock could drop to €30. The bank cautioned that without fresh R&D catalysts, Bayer cannot simply be treated as a cheap pharmaceutical play.

The immediate legal battleground revolves around the $7.25 billion Roundup settlement. The opt-out deadline falls on June 5, 2026, and CEO Bill Anderson has demanded an exceptionally high participation rate for the deal to proceed. Already facing pushback, a lawyer representing cancer patients is seeking to move the case to federal court, labelling the offered sum "outrageously low" and the exit terms too restrictive. If enough plaintiffs remain on board, a final hearing in a Missouri court is scheduled for July.

Should investors sell immediately? Or is it worth buying Bayer PK?

Parallel to that process, the U.S. Supreme Court is deliberating the Durnell case, with a decision expected by the end of June. A ruling in Bayer’s favour could eliminate as many as 80% of the outstanding lawsuits, providing a much more definitive resolution than the settlement alone. Until then, the stock remains exposed to sharp swings — the relative strength index currently sits at 57, indicating neither overbought nor oversold conditions.

On the charts, the Xetra stock found short-term support at Friday’s low of €35.95, while resistance sits around €38.50 — the closing price on May 22. The ADR equivalent has been tracking a similar pattern, hovering near its 200-day moving average.

Operationally, Bayer delivered solid first-quarter results earlier this month. Revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.4 billion, EBITDA before special items climbed 9% to €4.5 billion, and earnings per share gained 12.9% to €2.71. However, free cash flow remained deeply negative at minus €2.3 billion, weighed down by settlement payouts, and net financial debt stood at €32.5 billion. The company confirmed its currency-adjusted annual guidance while tweaking the reported range for foreign exchange effects.

With the opt-out deadline approaching and the Supreme Court ruling imminent, Bayer faces a period of binary outcomes. The raised analyst target reflects underlying asset value, but market scepticism has kept the shares pinned near technical support. The next weeks will test whether legal catalysts can break the stalemate — or deepen the discount.

Ad

Bayer PK Stock: New Analysis - 31 May

Fresh Bayer PK information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer PK analysis...

en | US0727303028 | BAYER | boerse | 69451270 |